Hudson Bay Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Hudson Bay Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-75,000	Closed	-$2.34M	–	1593
2025 Q4	$2.34M	Sell	75,000 -150,000	-67%	-$3.7M	0.01%	683
2025 Q3	$4.54M	Buy	225,000 +105,000	+88%	+$1.84M	0.02%	577
2025 Q2	$2.01M	Sell	120,000 -85,000	-41%	-$1.37M	0.01%	798
2025 Q1	$3.15M	Buy	+205,000	New	+$3.66M	0.01%	715
2020 Q4	–	Sell	-150,000	Closed	-$1.35M	–	708
2020 Q3	$1.35M	Buy	150,000 +80,000	+114%	+$846K	0.02%	396
2020 Q2	$863K	Sell	70,000 -30,000	-30%	-$339K	0.02%	389
2020 Q1	$898K	Buy	+100,000	New	+$1.02M	0.02%	339
2015 Q2	–	Sell	-300,000	Closed	-$18.7M	–	255
2015 Q1	$18.7M	Buy	+300,000	New	+$17.4M	0.5%	41
2014 Q4	–	Sell	-233,627	Closed	-$12.6M	–	221
2014 Q3	$12.6M	Sell	233,627 -105,000	-31%	-$5.56M	0.35%	64
2014 Q2	$17.8M	Sell	338,627 -135,000	-29%	-$6.9M	0.55%	53
2014 Q1	$25M	Buy	+473,627	New	+$21.9M	0.67%	40

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hudson Bay Capital Management's TEVA Position: Q1 2026 in Review

Hudson Bay Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 75,000 shares — an estimated $2.34M sold.

Hudson Bay Capital Management first reported a position in TEVA in Q1 2014 and held it in 11 quarters. The position peaked at $25M in Q1 2014. 652 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Hudson Bay Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Hudson Bay Capital Management sold 75,000 Teva Pharmaceuticals shares in Q1 2026, an estimated $2.34M.
Hudson Bay Capital Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 11 quarters.
Hudson Bay Capital Management's Teva Pharmaceuticals position peaked at $25M in Q1 2014.
652 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.